Rockwell Medical (RMTI) Upgraded to Hold by Zacks Investment Research
Rockwell Medical (NASDAQ:RMTI) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Thursday.
According to Zacks, “Rockwell Medical Technologies, Inc. manufactures hemodialysis concentrates and dialysis kits, and sells, distributes and delivers such concentrates and dialysis kits, as well as other ancillary hemodialysis products, to hemodialysis providers in the United States. Hemodialysis is a process which is able to duplicate kidney function in patients whose kidneys have failed to function properly. “
Several other research analysts have also weighed in on RMTI. BidaskClub raised Rockwell Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, August 11th. Ifs Securities assumed coverage on Rockwell Medical in a research report on Monday, August 14th. They set a “strong-buy” rating and a $11.00 price target on the stock.
Shares of Rockwell Medical (NASDAQ:RMTI) opened at $6.25 on Thursday. Rockwell Medical has a 52-week low of $5.06 and a 52-week high of $8.98.
Rockwell Medical (NASDAQ:RMTI) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). The firm had revenue of $14.63 million for the quarter, compared to analyst estimates of $13.33 million. Rockwell Medical had a negative return on equity of 46.63% and a negative net margin of 39.28%. Rockwell Medical’s quarterly revenue was up 14.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.09) earnings per share. equities analysts predict that Rockwell Medical will post -0.44 EPS for the current year.
A number of large investors have recently bought and sold shares of RMTI. Vanguard Group Inc. raised its position in Rockwell Medical by 4.9% during the first quarter. Vanguard Group Inc. now owns 1,990,057 shares of the company’s stock valued at $12,458,000 after buying an additional 93,589 shares during the period. Geode Capital Management LLC raised its position in Rockwell Medical by 9.7% during the first quarter. Geode Capital Management LLC now owns 371,700 shares of the company’s stock valued at $2,326,000 after buying an additional 32,964 shares during the period. KCG Holdings Inc. acquired a new position in Rockwell Medical during the first quarter valued at $111,000. Metropolitan Life Insurance Co. NY raised its position in Rockwell Medical by 11.3% during the first quarter. Metropolitan Life Insurance Co. NY now owns 42,220 shares of the company’s stock valued at $264,000 after buying an additional 4,287 shares during the period. Finally, Cutter & CO Brokerage Inc. raised its position in Rockwell Medical by 6.3% during the second quarter. Cutter & CO Brokerage Inc. now owns 25,325 shares of the company’s stock valued at $201,000 after buying an additional 1,500 shares during the period. 21.37% of the stock is currently owned by hedge funds and other institutional investors.
Rockwell Medical Company Profile
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.